A G-quadruplex-binding compound shows potent activity in human gemcitabine-resistant pancreatic cancer cells

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Gemcitabine is a primary treatment for pancreatic cancer, but chemo-resistance is a significant clinical challenge.
• Over 100 genes are implicated in gemcitabine resistance, necessitating alternative therapeutic strategies.
• G-quadruplex structures are increasingly recognized as targets for novel anti-cancer agents.

Purpose of the Study:

• To evaluate the efficacy of a novel G-quadruplex ligand, CM03, against gemcitabine-resistant pancreatic cancer.
• To investigate the molecular mechanisms underlying CM03's activity in resistant cell lines.
• To explore CM03 as a potential therapeutic agent for gemcitabine-refractory pancreatic cancer.

Main Methods:

• Generation of gemcitabine-resistant pancreatic cancer cell lines (MIA PaCa-2).
• Assessment of CM03 sensitivity in parental and resistant cell lines.
• Whole transcriptome analysis using RNA-sequencing (RNA-seq) to identify molecular changes.

Main Results:

• Gemcitabine-resistant cell lines exhibited up to 1,000-fold reduced sensitivity to gemcitabine but retained nanomolar sensitivity to CM03.
• RNA-seq analysis revealed that CM03's pathway modulation patterns were largely preserved in resistant cells.
• CM03 treatment downregulated genes associated with gemcitabine sensitivity in the resistant cell line.

Conclusions:

• CM03 demonstrates significant potential as a therapeutic agent for gemcitabine-resistant pancreatic cancer.
• The G-quadruplex ligand CM03 overcomes common chemo-resistance mechanisms.
• Further investigation into CM03 is warranted for clinical application in pancreatic cancer treatment.